To increase the apoptotic effects of docetaxel in prostate cancer cells and overcome resistance, synergistic treatment with recombinant GLIPR1 (GLIPR1-DTM) inhibited tumor growth, consequently enhancing the chemotherapy effect[139]. Here, GLIPR1 is linked to prostate cancer.